Abstract

Until recently, contraceptive product development, the translation of a research finding into a final product, was successfully carried out by profit-making, commercial pharmaceutical companies. Interaction between commercial companies, scientists, and drug-regulatory agencies has defined the steps necessary for development of a safe, acceptable, and economically feasible product. Expected financial returns from sales of the final product have driven the development process.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call